Neoprobe Corporation (NEOP) Receives Cellular Therapy Technology Assessment; Positive Technology Review And Clinical Recommendations Received
10/19/2005 5:10:53 PM
DUBLIN, Ohio--(BUSINESS WIRE)--April 26, 2005--Neoprobe Corporation (OTCBB:NEOP), a diversified developer of innovative oncology and cardiovascular surgical and diagnostic products, today announced that its subsidiary, CIRA Biosciences, Inc. (CIRA Bio), has received an independent technology assessment report on its activated cellular therapy (ACT) technology. The recently completed assessment was performed by the Battelle Memorial Institute (Battelle) for the purpose of reviewing the cell processing procedures and manufacturing processes used by CIRA Bio in earlier ACT clinical trials that provided positive clinical results. The Battelle report indicates that the ACT cell processing technology would be commercially feasible and reproducible with CIRA Bio's implementation of the recommended Battelle process and procedure development initiatives.
In addition to evaluating the technology's commercial manufacturing feasibility, Battelle identified a number of laboratory processing and handling procedures that could be consolidated thereby improving cell processing efficiency and potentially reducing processing costs. The Battelle assessment also made a number of observations and specific recommendations concerning the next phases of development for the manufacturing process. Following are some of the more significant observations:
comments powered by